Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1 1

Status

Completed 2Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 4Other solid neoplasm 1Head & Neck 1

Conditions

Melanoma 4Skin Neoplasms 1Neoplasm Metastasis 1Diabetes Mellitus, Insulin-Dependent, 12 1

Interventions

pembrolizumab 326Nivolumab 289Ipilimumab 260Cyclophosphamide 194aldesleukin 145Interleukin-2 109fludarabine phosphate 107Temozolomide 83fludarabine 81Dacarbazine 81Radiotherapy 74trametinib 73Vemurafenib 69dabrafenib 66Biopsy 65sargramostim 50Bevacizumab 50Radiosurgery 49Paclitaxel 49Peripheral Blood Stem Cell Transplantation 48Magnetic Resonance Spectroscopy 48Carboplatin 48Imiquimod 47Aminolevulinic Acid 47binimetinib 45Cisplatin 45CTLA-4 Antigen 43cemiplimab 42Specimen Handling 42atezolizumab 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × tilsotolimod × Dermatologic × Clear all
NCT03445533 2022-11-08

A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma

Idera Pharmaceuticals, Inc.

Phase 3 Terminated
481 enrolled 22 charts
Dermatologic

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma, Neoplasm Metastasis, Skin Neoplasms

NCT02644967 2022-08-03

ILLUMINATE-204

Idera Pharmaceuticals, Inc.

Phase 2 Completed
53 enrolled 21 charts
Dermatologic

Melanoma

NCT04126876 2021-04-15

INTRIM

Amsterdam UMC, location VUmc

Phase 2 Recruiting
214 enrolled
Dermatologic

Melanoma

NCT03052205 2020-02-11

ILLUMINATE-101

Idera Pharmaceuticals, Inc.

Phase 1 Completed
54 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡